TMEM183A

Summary

TMEM183A (transmembrane protein 183A, HGNC:20173) is a protein-coding gene on chromosome 1q32.1, encoding Transmembrane protein 183A (Q8IXX5). It is a selective cancer dependency (DepMap: 34.2% of cell lines).

Predicted to be located in membrane. Predicted to be part of SCF ubiquitin ligase complex.

Source: NCBI Gene 92703 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 52 total
• Cancer dependency (DepMap): dependent in 34.2% of screened cell lines
• MANE Select transcript: NM_138391

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20173
Approved symbol	TMEM183A
Name	transmembrane protein 183A
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000163444
Ensembl biotype	protein_coding
Entrez	92703

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 17 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000367242, ENST00000463015, ENST00000468449, ENST00000488097, ENST00000543891, ENST00000881137, ENST00000881138, ENST00000881139, ENST00000881140, ENST00000881141, ENST00000881142, ENST00000881143, ENST00000881144, ENST00000881145, ENST00000881146, ENST00000912607, ENST00000912608, ENST00000912609, ENST00000965091, ENST00000965092, ENST00000965093

RefSeq mRNA: 8 — MANE Select: NM_138391 NM_001322955, NM_001322956, NM_001322957, NM_001322958, NM_001322959, NM_001349859, NM_001349862, NM_138391

CCDS: CCDS1432

Canonical transcript exons

ENST00000367242 — 8 exons

Exon	Start	End
ENSE00001074660	203020793	203020948
ENSE00001443918	203022855	203024848
ENSE00001443921	203007374	203007574
ENSE00003473396	203014889	203015048
ENSE00003486591	203015960	203016140
ENSE00003515111	203007774	203007863
ENSE00003667954	203008643	203008810
ENSE00003671496	203018481	203018561

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 96.27.

FANTOM5 (CAGE): breadth broad, TPM avg 1.2204 / max 25.0981, expressed in 802 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
7828	24.2784	1821
7829	1.2204	802

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
rectum	UBERON:0001052	96.27	gold quality
cortical plate	UBERON:0005343	95.82	gold quality
monocyte	CL:0000576	95.44	gold quality
mononuclear cell	CL:0000842	95.33	gold quality
leukocyte	CL:0000738	95.29	gold quality
transverse colon	UBERON:0001157	95.08	gold quality
granulocyte	CL:0000094	94.94	gold quality
body of pancreas	UBERON:0001150	94.91	gold quality
mucosa of transverse colon	UBERON:0004991	94.91	gold quality
prefrontal cortex	UBERON:0000451	94.90	gold quality
left testis	UBERON:0004533	94.74	gold quality
cerebellar hemisphere	UBERON:0002245	94.64	gold quality
cerebellar cortex	UBERON:0002129	94.61	gold quality
right testis	UBERON:0004534	94.57	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.56	gold quality
mucosa of stomach	UBERON:0001199	94.27	gold quality
islet of Langerhans	UBERON:0000006	94.25	gold quality
skin of abdomen	UBERON:0001416	94.22	gold quality
anterior cingulate cortex	UBERON:0009835	94.19	gold quality
cingulate cortex	UBERON:0003027	94.14	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.02	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.01	gold quality
lower esophagus	UBERON:0013473	94.00	gold quality
right frontal lobe	UBERON:0002810	93.94	gold quality
right lung	UBERON:0002167	93.90	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.90	gold quality
skin of leg	UBERON:0001511	93.89	gold quality
popliteal artery	UBERON:0002250	93.88	gold quality
tibial artery	UBERON:0007610	93.88	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.86	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-124858	no	152.36
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting TMEM183A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-642A-5P	99.51	65.10	1152
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-4696	99.48	67.48	1040
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-150-3P	99.43	70.51	920
HSA-MIR-1244	99.33	68.38	832
HSA-MIR-6828-5P	99.31	69.21	1433

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 34.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• c1orf37-dup encodes a novel transmembrane protein in humans which potentially endows new properties to cell surface interactions (PMID:16644869)
• B4GALT3, DAP3, RGS16, TMEM183A and UCK2–were significantly overexpressed in dup(1q)-positive ALLs compared with high hyperdiploid ALLs without dup(1q). (PMID:17613536)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem183a	ENSDARG00000044899
mus_musculus	Tmem183a	ENSMUSG00000042305
rattus_norvegicus	Tmem183a	ENSRNOG00000003594
drosophila_melanogaster	fsd	FBGN0033813

Protein

Protein identifiers

Transmembrane protein 183A — Q8IXX5 (reviewed: Q8IXX5)

All UniProt accessions (1): Q8IXX5

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the TMEM183 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IXX5-1	1	yes
Q8IXX5-2	2

RefSeq proteins (8): NP_001309884, NP_001309885, NP_001309886, NP_001309887, NP_001309888, NP_001336788, NP_001336791, NP_612400* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026509	TMEM183	Family
IPR036047	F-box-like_dom_sf	Homologous_superfamily

UniProt features (8 total): region of interest 2, sequence variant 2, chain 1, transmembrane region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IXX5-F1	73.91	0.47

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 158 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, TGGTGCT_MIR29A_MIR29B_MIR29C, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, MORF_SKP1A, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, MORF_PPP6C, CREB_Q3, BOYAULT_LIVER_CANCER_SUBCLASS_G12_UP, ACEVEDO_LIVER_CANCER_UP, SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY, GOCC_SCF_UBIQUITIN_LIGASE_COMPLEX, GOCC_TRANSFERASE_COMPLEX, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, GOCC_CULLIN_RING_UBIQUITIN_LIGASE_COMPLEX, GOCC_UBIQUITIN_LIGASE_COMPLEX

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): membrane (GO:0016020), SCF ubiquitin ligase complex (GO:0019005)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cellular anatomical structure	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

698 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM183A	RNF13	O43567	588
TMEM183A	HSF2BP	O75031	560
TMEM183A	VRK2	Q86Y07	530
TMEM183A	ERVFRD-1	P60508	490
TMEM183A	ERV3-1	Q14264	490
TMEM183A	NUS1	Q96E22	474
TMEM183A	TLK2	Q86UE8	463
TMEM183A	TMEM47	Q9BQJ4	418
TMEM183A	ARIH2	O95376	416
TMEM183A	TTC7B	Q86TV6	410
TMEM183A	TMEM134	Q9H6X4	405
TMEM183A	DAB2	P98082	397
TMEM183A	UHRF1	Q96T88	395
TMEM183A	PCMT1	P22061	387
TMEM183A	BMPR1A	P36894	387

IntAct

29 interactions, top by confidence:

A	B	Type	Score
IFIT3	TMEM183A	psi-mi:“MI:0915”(physical association)	0.780
TMEM183A	IFIT3	psi-mi:“MI:0915”(physical association)	0.780
SYP	APBB1	psi-mi:“MI:0914”(association)	0.530
GPN1	POLR3A	psi-mi:“MI:0914”(association)	0.530
TMEM183A		psi-mi:“MI:0915”(physical association)	0.370
IFIT3	HSPA1B	psi-mi:“MI:0914”(association)	0.350
SYP	APBB1	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	GXYLT2	psi-mi:“MI:0914”(association)	0.350
HCST	TMEM120B	psi-mi:“MI:0914”(association)	0.350
LRRC55	TMEM120B	psi-mi:“MI:0914”(association)	0.350
HIDE1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
PIPSL	C1orf226	psi-mi:“MI:0914”(association)	0.350
GYPA	HYKK	psi-mi:“MI:0914”(association)	0.350
PTGES3	SBNO1	psi-mi:“MI:0914”(association)	0.350
RNF149	CCDC85C	psi-mi:“MI:0914”(association)	0.350
TMEM183A	MYH7B	psi-mi:“MI:0914”(association)	0.350
IFNLR1	AURKA	psi-mi:“MI:0914”(association)	0.350
KLRD1	PRORP	psi-mi:“MI:0914”(association)	0.350
GPR182	SLC12A8	psi-mi:“MI:0914”(association)	0.350
SYP	HAS3	psi-mi:“MI:0914”(association)	0.350
TMEM183A	DNM1L	psi-mi:“MI:0914”(association)	0.350
LRRC25	SCAMP3	psi-mi:“MI:0914”(association)	0.350
PPP1R15A	BARD1	psi-mi:“MI:0914”(association)	0.350
TMEM183A	IFIT3	psi-mi:“MI:0915”(physical association)	0.000
	TMEM183A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (31): TMEM183A (Two-hybrid), TMEM183A (Affinity Capture-MS), TMEM183A (Two-hybrid), ACTN3 (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), MYH7B (Affinity Capture-MS), TMEM183A (Affinity Capture-MS), TMEM183A (Affinity Capture-MS)

ESM2 similar proteins: A0JMQ9, A2BD94, A2RRT3, A8WHR0, B2RYN2, D3ZKV9, O36371, O43147, P03177, P41958, Q0D2D2, Q1HVD1, Q1LVQ2, Q2NKQ1, Q3KSQ2, Q3TQF0, Q4R8E0, Q4V8Z3, Q5EA86, Q5R8D5, Q5U228, Q5U430, Q5XUX0, Q68FS7, Q6INH1, Q6NU22, Q6NU51, Q6ZN28, Q6ZUJ8, Q7ZUL9, Q80TM9, Q80U12, Q84WW1, Q8AXQ3, Q8BMQ2, Q8BPQ7, Q8IXX5, Q8SX86, Q9BQI3, Q9D5Z5

Diamond homologs: Q1AE95, Q5EA86, Q5R8D5, Q68FS7, Q8IXX5, Q9JJB9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1782 predictions. Top by Δscore:

Variant	Effect	Δscore
1:203007531:A:T	donor_gain	1.0000
1:203007859:GGAAG:G	donor_gain	1.0000
1:203007860:GAAGG:G	donor_gain	1.0000
1:203007861:A:T	donor_gain	1.0000
1:203007861:AAGG:A	donor_loss	1.0000
1:203007862:AGGTA:A	donor_loss	1.0000
1:203007863:GGTA:G	donor_loss	1.0000
1:203007864:G:A	donor_loss	1.0000
1:203007865:T:A	donor_loss	1.0000
1:203008641:A:AG	acceptor_gain	1.0000
1:203008642:G:GA	acceptor_gain	1.0000
1:203008642:GT:G	acceptor_gain	1.0000
1:203008642:GTA:G	acceptor_gain	1.0000
1:203008642:GTAA:G	acceptor_gain	1.0000
1:203008642:GTAAA:G	acceptor_gain	1.0000
1:203008809:AGGTA:A	donor_loss	1.0000
1:203008811:G:GG	donor_gain	1.0000
1:203008811:GT:G	donor_loss	1.0000
1:203008812:T:A	donor_loss	1.0000
1:203014888:GAA:G	acceptor_gain	1.0000
1:203014986:GATTT:G	donor_gain	1.0000
1:203014991:G:GG	donor_gain	1.0000
1:203016137:CAAA:C	donor_gain	1.0000
1:203016138:AAA:A	donor_gain	1.0000
1:203016138:AAAG:A	donor_loss	1.0000
1:203016139:AA:A	donor_gain	1.0000
1:203016140:AG:A	donor_loss	1.0000
1:203016141:GTAA:G	donor_gain	1.0000
1:203016142:T:G	donor_loss	1.0000
1:203018479:A:AG	acceptor_gain	1.0000

AlphaMissense

2457 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:203014933:T:A	W138R	0.999
1:203014933:T:C	W138R	0.999
1:203015029:T:A	W170R	0.999
1:203015029:T:C	W170R	0.999
1:203022870:A:C	S321R	0.999
1:203022871:G:T	S321I	0.999
1:203022872:C:A	S321R	0.999
1:203022872:C:G	S321R	0.999
1:203022881:G:A	M324I	0.999
1:203022881:G:C	M324I	0.999
1:203022881:G:T	M324I	0.999
1:203023002:T:A	W365R	0.999
1:203023002:T:C	W365R	0.999
1:203023005:T:A	W366R	0.999
1:203023005:T:C	W366R	0.999
1:203007792:C:A	A43D	0.998
1:203014978:T:C	F153L	0.998
1:203014979:T:C	F153S	0.998
1:203014980:T:A	F153L	0.998
1:203014980:T:G	F153L	0.998
1:203015026:T:C	F169L	0.998
1:203015028:T:A	F169L	0.998
1:203015028:T:G	F169L	0.998
1:203018532:T:A	W254R	0.998
1:203018532:T:C	W254R	0.998
1:203020887:T:C	L295P	0.998
1:203022892:G:C	R328P	0.998
1:203015031:G:C	W170C	0.997
1:203015031:G:T	W170C	0.997
1:203018481:T:C	C237R	0.997

dbSNP variants (sampled 300 via entrez): RS1000190081 (1:203011962 A>G), RS1000315857 (1:203019260 C>T), RS1000412421 (1:203019197 A>G), RS1000527530 (1:203013558 C>G), RS1000643338 (1:203013913 C>T), RS1000647857 (1:203012477 C>A,T), RS1000701825 (1:203020428 C>T), RS1000943491 (1:203012185 C>T), RS1001443675 (1:203007392 C>G,T), RS1001497467 (1:203005978 C>T), RS1001645827 (1:203025234 T>G), RS1002039335 (1:203011844 G>A,T), RS1002042568 (1:203005896 C>G), RS1002224870 (1:203006026 T>G), RS1002276183 (1:203018879 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	increases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
methylparaben	increases expression	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
Leflunomide	increases expression	1
Benzo(a)pyrene	decreases expression	1
Doxorubicin	decreases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer